Sai Life Sciences Moat Analysis: Score & Risks
Sai Life Sciences Ltd.
A first-pass moat teardown of Sai Life Sciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Sai Life Sciences Ltd. scores 5.12 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our PAT saw a 105% increase over the previous year driven by operating leverage and improved efficiencies.”
“so far, we have not had any pricing pressure. We have held up pricing . It is business as usual from a pricing standpoint. We have not seen any pricing pressure yet.”
“Proprietary, GMP-enabled digital systems ensure compliance, data integrity, and global regulatory alignment across every function.”
“The Company has a 16-member business development team, distributed across US, UK, Europe, and India responsible for continuing and expanding customer relationships.”
“Commercial supply qualification received from two additional large pharma customers”
“Sure. I think to start with, I think the question on capacity utilization, I think we had a very good capacity utilization of 67% for the last financial year.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion